secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001493152-22-005761
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics terminates Chief Medical Officer Dr. G. Dave Singh for cause, effective March 1, 2022
--------------------------------------------------------------------------------

- Dr. Singh was terminated for cause per his employment agreement dated October 9, 2020.
- He had been on sabbatical since September 2021 as Adjunct Professor at Stanford University.
- Company has reallocated his responsibilities to other personnel and expects no significant operational impact.
- Dr. Singh is no longer affiliated with Vivos as of March 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315222005761/0001493152-22-005761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315222005761/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-005761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer